Webcasts

***Live: Wednesday, November 18, 2020 at 10am EST | 9am CST | 3pm GMT | 4pm CET***Learn how automating mass spectrometry (MS)-based site-specific glycosylation monitoring of biotherapeutics can increase throughput and improving data quality in glycosylation monitoring of biotherapeutics.***On demand available after final airing until NOV. 18, 2021***

An Automated MS Data Workflow Enabling Targeted, Site-Specific Glycosylation Monitoring of Biopharmaceuticals

***Live: Tuesday, November 17, 2020 at 8am PST| 11am EST| 4pm GMT| 5pm CET***Shine a light on the (co-)formulation and stability one or more proteins.***On demand available after final airing until NOV. 17, 2021***

Rational use of Dynamic Light Scattering for the Characterization of Cytokines, Bispecific Antibody Fusion Proteins, and Binary Antibody Mixtures

***Live: Tuesday, November 3, 2020 at 11am EST| 8am PST| 4pm GMT| 5pm CET*** In this webcast, learn how multi-attribute assays were used to accelerate routine workflows for biotherapeutics characterization at the intact and subunit level. This new streamlined approach increased the efficiency to perform stability assessment of antibody-drug onjugates (ADC) significantly.***On demand available after final airing until Nov. 3, 2021***

Intact and Subunit MAM Assays Accelerate the Development of Antibody-Drug Conjugates

*** Live: Wednesday, November 11, 2020 | 8:30 AM EDT – 4:00 PM EDT *** 2020 Bio/Pharma Virtual Congress: Join Pharmaceutical Technology® and BioPharm International® for this online event that will explore the latest developments in formulation, manufacturing, and innovative drug dosage forms, as well as detailed discussions about crucial topics impacting the industry. ***On demand available after final airing until 11/11/2021***

2020 Bio/Pharma Virtual Congress

*** Two Live Events! Monday, Oct. 26, 2020 at 9am EDT| 1pm GMT| 2pm CET and Monday, Oct. 26, 2020 at 2pm EDT| 1pm CDT| 11am PDT*** Join us for this web seminar to learn about the utility of mass spectrometry for characterizing adeno-associated viruses (AAVs), including how intact mass spectrometry can accurately confirm AAV capsid proteins, how AAV post-translational modifications can be identified and confirmed, and how upfront sample preparation can improve mass spec accuracy and resolution. ***On demand available after final airing until Oct. 26, 2021***

Characterization of Viral Vector Particles with LC–MS

*** Three Events: Tuesday, Oct. 27, 2020 at 11am EDT| 8am PDT| 3pm GMT| 4pm CET Asia Pacific: Wednesday, Oct. 28, 2020 at 10:30 am IST| 1pm CST| 2pm JST Europe: Wednesday, Oct. 28, 2020 at 9am| 10am CET*** Characterizing complex nanoparticles, polymers and biotherapeutics is about to get a lot easier. ***On demand available after final airing until Oct. 28, 2021***

Breakthroughs in FFF-MALS – New Levels of Performance and Usability

***Live: Thursday, Oct. 22, 2020 at 10am EDT| 9am CDT| 3pm BST| 4pm CEST***Process development for anchorage-dependent cells at bench scale is crucial to establish cost-efficient workflows in larger volumes. Learn how different process parameter can be monitored and controlled in a perfusion bioprocess and the potential of using packed-bed bioreactors or a microcarrier spin filter for attachment cell-based vaccine production.. *** On demand available after final airing until Oct. 22, 2021.***

Vero Cell Cultivation for Vaccine Production 

***Live: Wednesday, Oct. 21, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST*** Host cell proteins (HCPs) can compromise a biologic drug and delay its development program. Learn about important considerations for optimizing HCP testing in this webcast. ***On demand available after final airing until Oct. 21, 2021***

Host Cell Proteins: Analytical and Regulatory Challenges

***Live: Wednesday, Oct. 14, 2020, at 11am EDT| 8am PDT| 4pm BST| 5pm CEST*** Hear experts review key milestones and tasks—as well as potential stumbling blocks—along the drug development pathway and offer strategies to help discovery-phase drug development programs move from the lab to clinic and commercialization. *** On demand available after final airing until Oct. 14, 2021.***

Editors’ Series: Mapping the Transition from Drug Discovery to Development and Beyond

Non-infectious mock virus particles that mimic the physicochemical properties of live infectious
viruses can be used as spiking agents during viral clearance testing. Review results from several studies using an economical spiking surrogate—a non-infectious minute virus of mice-mock virus particle (MVM-MVP)—to demonstrate viral clearance in industrial processes. 

Tuesday, Oct 6, 2020 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST
On demand available after final airing until Oct. 6, 2021.